1CM (MILFF) 3-Year RORE % : 184.62% (As of Feb. 2026)


MILFF 1CM Inc MILFF
50 GF Score
Price $0.08
GF Value $0.31
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is 1CM 3-Year RORE %?

1CM MILFF 50 3-Year RORE % is 184.62 as of Feb. 2026. GuruFocus rates MILFF with a GF Score™ of 50/100 and a GF Value™ of $0.31 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 936 Drug Manufacturers companies, 1CM ranks better than 95.3% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. 1CM's 3-Year RORE % for the quarter that ended in Feb. 2026 was 184.62%.

The industry rank for 1CM's 3-Year RORE % or its related term are showing as below:

MILFF's 3-Year RORE % is ranked better than
95.3% of 936 companies
in the Drug Manufacturers industry
Industry Median: 3.075 vs MILFF: 184.62

1CM  (OTCPK:MILFF) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


1CM 3-Year RORE % Related Terms


1CM 3-Year RORE % Historical Data

* Premium members only.

The historical data trend for 1CM's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

1CM 3-Year RORE % Chart

1CM Annual Data
Trend Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24 Aug25
3-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -66.16 7.27 -38.37 -102.38 0.00

1CM Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -119.23 -150.00 0.00 -41.67 184.62

MILFF vs ZTS, UTHR: 3-Year RORE % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, 1CM's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


1CM 3-Year RORE % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, 1CM's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where 1CM's 3-Year RORE % falls into.


MILFF
50GF Score
1CM Inc MILFF
3-Year RORE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

1CM 3-Year RORE % Calculation

1CM's 3-Year RORE % for the quarter that ended in Feb. 2026 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( 0.015--0.009 )/( 0.013-0 )
=0.024/0.013
=184.62 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Feb. 2026 and 3-year before.

Frequently Asked Questions Learn more about 3-Year RORE % →
What does a 3-Year RORE % of 184.62 mean?
1CM (MILFF) has a 3-Year RORE % of 184.62 as of Feb. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on 1CM and its competitors. According to the industry distribution chart, 1CM ranks #44 out of 936 companies in the Drug Manufacturers industry, placing it in the top 4.7%.
Is 1CM's 3-Year RORE % too high?
1CM's current 3-Year RORE % is 184.62. The Drug Manufacturers industry median 3-Year RORE % is 3.08. 1CM's value of 184.62 is 5903.9% above this industry median. Based on the distribution chart, 1CM ranks #44 out of 936 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, 1CM has a GF Score™ of 50/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does 1CM's 3-Year RORE % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, 1CM ranks #44 out of 936 companies for 3-Year RORE %. This places 1CM in the top 5% of its industry — outperforming the majority of peers. The industry median 3-Year RORE % is 3.08. 1CM's value of 184.62 is 5903.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Drug Manufacturers company?
The median 3-Year RORE % among Drug Manufacturers companies is 3.08, based on 936 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. 1CM's current 3-Year RORE % of 184.62 is 5903.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on 1CM and its competitors. For the Drug Manufacturers industry, the median 3-Year RORE % is 3.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 1CM's current 3-Year RORE % is 184.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 1CM stock overvalued right now?
Based on GuruFocus' analysis, 1CM (MILFF) is currently considered Significantly Undervalued. The stock's GF Value™ is $0.31, compared to a current price of $0.08 — trading 74.8% below its estimated fair value. The current 3-Year RORE % is 184.62 and 5903.9% above the Drug Manufacturers industry median of 3.08. 1CM's overall GF Score™ is 50/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For 1CM (MILFF), the current 3-Year RORE % is 184.62 as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is 1CM (MILFF) Overvalued in 2026?

Based on GuruFocus' analysis, 1CM stock appears to be undervalued. The current stock price of $0.08 is trading 74.8% below its estimated GF Value™ of $0.31. GuruFocus considers 1CM to be Significantly Undervalued.

Key valuation signals for MILFF:

  • 3-Year RORE %: 184.62
  • GF Value™: $0.31 vs. price of $0.08 (74.8% below fair value)
  • GF Score™: 50/100 with 3 warning signs
  • Industry Position: 5903.9% above the Drug Manufacturers median (#44 of 936)

No single metric tells the full story. See the MILFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


1CM Business Description

Other Exchanges EPIC:Canada
Address 625 Cochrane Drive, Suite 802, Markham, ON, CAN, L3R9R9
1CM Inc is a multi-jurisdictional cannabis company focused on its retail customers and technology to democratize cannabis markets. The Company focuses on expanding its current operations through organic growth and by way of merger and acquisition transactions. It has a single operating segment, being Cannabis.
50GF Score

Get the complete analysis for MILFF

3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.08
Price
$0.31
GF Value